Source Fact: Financial Supervisory Service DART / 2024-03-11
Disclosure Type: Resolution on Convening of General Meeting of Shareholders
💡 3-Second Summary
Alteogen’s board has resolved to hold its 16th Annual General Meeting of Shareholders at the Daejeon Convention Center on March 26 at 9:00 AM KST, presenting six major agendas including the new appointment of U.S. Patent Attorney and VP Tae-Yeon Jeon as an Inside Director.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Filing Entity: Alteogen Co., Ltd. (Ticker: 196170)
- Meeting Classification: Annual General Meeting of Shareholders
- Date, Time, and Location:
- Date & Time: March 26, 2024 (09:00 AM Local Time)
- Location: Medium Conference Room, 1st Floor, Daejeon Convention Center, 107 Expo-ro, Yuseong-gu, Daejeon
- Proposed Agendas:
- Reporting Items: Audit Report, Business Report, Report on the Operations of Internal Accounting Control System
- Agenda No. 1: Approval of the 16th Fiscal Year Consolidated and Separate Financial Statements
- Agenda No. 2 (Appointment of Directors): New appointment of Tae-Yeon Jeon as Inside Director (3-year term); Re-appointment of In-Young Ko as Outside Director (3-year term); New appointment of Sang-Cheol Lee as Outside Director
- Agenda No. 3: Re-appointment of Byung-Gyu Lee as Standing Auditor (3-year term)
- Agenda No. 4 & No. 5: Approval of compensation limits for Directors and the Auditor
- Agenda No. 6: Approval of stock option grants
- Key Nominee Profiles:
- Inside Director Nominee Tae-Yeon Jeon: Current Vice President & CAO of Alteogen, Ph.D. in Biochemistry from Univ. of Wisconsin-Madison, J.D. from Indiana University, U.S. Patent Attorney.
- Outside Director Nominee In-Young Ko: Current Outside Director of Alteogen, Professor of Ocular Biomedical Engineering at Kangwon National University.
- Outside Director Nominee Sang-Cheol Lee: Current Vice President of the Korean Society for Biochemistry and Molecular Biology (KSBMB), Former Director of National Agenda Research Division at Korea Research Foundation.
- Standing Auditor Nominee Byung-Gyu Lee: Current Standing Auditor of Alteogen, Former Corporate Banking Branch Manager at Hana Bank.
- Board Decision Date: March 11, 2024 (Attended by 2 Outside Directors and the Auditor)
📈 2. [Expert View: What This Disclosure Means for Investors]
This regulatory filing serves as a statutory preliminary announcement required by the Commercial Act and capital market regulations to officially convene the regular annual assembly for corporate settlement and organizational adjustments. The board’s resolution to call a shareholders’ meeting does not induce immediate shifts in corporate earnings, asset valuations, or biological pipeline progressions, and should be evaluated strictly as a routine administrative event.
From a corporate governance perspective, market participants could observe the impending structural updates within the board composition. The inside director nominee, Vice President Tae-Yeon Jeon, carries highly specialized credentials, holding both a Ph.D. in biochemistry and a legal qualification as a U.S. patent attorney. If approved at the upcoming meeting, his formal entry into the executive board may bring a potential impact on optimizing global intellectual property (IP) defenses and reinforcing cross-border out-licensing negotiations over the long horizon. Furthermore, because the prior fiscal year’s audited financials are slated for final adoption under Agenda No. 1, a measured analytical approach requires tracking the upcoming formal audit report filings and verified voting outcomes on the meeting date (March 26) rather than forecasting early market directions.
📝 Editor’s Comment (by K-STOCK Editor)
Alteogen has set its administrative timeline for the regular general shareholders’ meeting to finalize its corporate books and fortify board-level competencies. The core structural variable outlined in this filing is the executive nominee lineup. Nominated for the inside board, Vice President Tae-Yeon Jeon offers a rare structural profile combining biochemical expertise with legal standing as a U.S. patent attorney. His prospective inclusion provides the company with an upgraded corporate governance framework to insulate its subcutaneous platform patents and manage complex international contracts. Since the resolution itself represents a routine procedural step, investors would be well-advised to track verified subsequent filings—such as the upcoming audited balance sheets and final voting metrics on March 26—rather than relying on unconfirmed theories within retail investment channels.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on the official data submitted to the Electronic Disclosure System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
